Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis.

ABSTRACT:

Background

Precision oncology is advancing, increasing the demand for comprehensive, non-invasive genomic profiling tools. Liquid biopsy using circulating tumor DNA (ctDNA) enables real-time molecular profiling, treatment monitoring, and early detection of resistance variants. We developed the PAN100 panel (Dxome), a hybridization capture panel targeting 101 genes, as a pan-cancer genotyping assay to detect clinically actionable variants across various cancer types. This study presents the first comprehensive validation of the PAN100 panel including both analytical and clinical performance across eight cancer types using reference materials and matched tissue samples.

Methods

For analytical validation, we assessed accuracy, limit of detection (LoD), and precision using Seras

SUBMITTER: Lim S 

PROVIDER: S-EPMC12915377 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature